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Dopamine neurotransmitter and its receptors play a critical role in
the cell signaling process responsible for information transfer in
neurons functioning in the nervous system. Development of im-
proved therapeutics for such disorders as Parkinson’s disease and
schizophrenia would be significantly enhanced with the availabil-
ity of the 3D structure for the dopamine receptors and of the
binding site for dopamine and other agonists and antagonists. We
report here the 3D structure of the long isoform of the human D2
dopamine receptor, predicted from primary sequence using first-
principles theoretical and computational techniques (i.e., we did
not use bioinformatic or experimental 3D structural information in
predicting structures). The predicted 3D structure is validated by
comparison of the predicted binding site and the relative binding
affinities of dopamine, three known dopamine agonists (antipar-
kinsonian), and seven known antagonists (antipsychotic) in the D2
receptor to experimentally determined values. These structures
correctly predict the critical residues for binding dopamine and
several antagonists, identified by mutation studies, and give rel-
ative binding affinities that correlate well with experiments. The
predicted binding site for dopamine and agonists is located be-
tween transmembrane (TM) helices 3, 4, 5, and 6, whereas the best
antagonists bind to a site involving TM helices 2, 3, 4, 6, and 7 with
minimal contacts to TM helix 5. We identify characteristic differ-
ences between the binding sites of agonists and antagonists.
W ith the implication of G protein-coupled receptor (GPCR)in many diseases (1, 2), the need to solve the high-
resolution 3D structure of this class of integral membrane
proteins to enable structure-based drug design is an important
problem in structural biology. Despite the importance of solving
the structure of the GPCRs, the only experimental 3D structure
available for a GPCR is bovine rhodopsin. This lack of structures
is because the GPCRs are bound to the membrane, making it
difficult to express in sufficient quantities for crystallization.
To provide structural and ligand binding information on
GPCRs, we have been developing first-principles computational
techniques for predicting the 3D structure of GPCRs using only
the amino acid sequence (MembStruk) and for predicting bind-
ing site and binding energy of various ligands to GPCRs (Hier-
Dock). Using these techniques, we have reported the structure
of olfactory receptors (3, 4), bovine rhodopsin (4, 5), and other
GPCRs (4).
Dopamine neurotransmitter plays a critical role in cellular
signaling processes responsible for information transfer in neu-
rons functioning in the nervous system (6, 7). Dopamine recep-
tors (DR) belong to the superfamily of GPCRs, and to date there
are five reported sequences for the human DR with multiple
isoforms for each. The DRs may be subdivided based on their
pharmacological behavior into the D1-like and the D2-like
subfamilies, and these are ideal targets for treating schizophrenia
and Parkinson’s disease; therefore, development of improved
remedies would be significantly enhanced with the availability of
the 3D structure for the DR and of the dopamine-binding site.
We report here the 3D structure of the long isoform of human
D2 DR, hereafter referred to as D2DR, predicted from primary
sequence using the MembStruk (3–5) and HierDock (3) first-
principles theoretical and computational techniques. The struc-
ture is validated by predicting the binding site and relative
binding affinities of dopamine, three known dopamine agonists,
and seven known antagonists. The predicted binding site for
dopamine and agonists is located between transmembrane (TM)
helices 3, 4, 5, and 6, whereas the best antagonists bind to a site
involving TM helices 2, 3, 4, 6, and 7 with minimal contacts to
TM helix 5. The predicted binding sites contain the critical
residues for binding dopamine and several antagonists that have
been identified by mutation studies and give relative binding
affinities that correlate well with experiment.
Computational Methods
All calculations for the protein used the DREIDING force field
(FF) (8) with charges from CHARMM22 (9) unless specified
otherwise. The non-bond interactions were calculated by using
the cell multipole method (10) in MPSim (11). The ligands were
described with the DREIDING FF using Gasteiger charges (12).
For the lipids we used the DREIDING FF with QEq charges
(13). All of the calculations treated the solvent (water) using the
analytical volume generalized born approximation to the Pois-
son–Boltzmann solvation model (14).
MembStruk Structure Prediction Method for D2DR. The MembStruk
procedure (MembStruk3.5), used to predict the 3D structure of
D2DR, is described in ref. 5. Here we detail the steps that are
relevant to the prediction of D2DR. The various steps of the
MembStruk3.5 as applied to D2DR are as follows.
TM prediction. The seven TM boundaries of the human D2DR
were predicted by using the TM2ndS (5) procedure. Seven
sequences with bit score200 in the BLAST (15) search of D2DR
were aligned by using multiple sequence alignment program
CLUSTALW (16). This alignment was used to predict the TM
regions using TM2ndS. It is shown that the seven TM helices in
D2DR are of different lengths and also are different in length
from the corresponding TM helices of bovine rhodopsin.
Optimization of the relative translation of helices. TM2ndS also pre-
dicts the hydrophobic center along each helix used for optimizing
the relative translational position of the TM helices. The seven
canonical -helices were built and the helical axes were posi-
tioned based on the 7.5-Å 3D density map of frog rhodopsin (17).
Relative translational orientation of the helices was optimized by
fitting the hydrophobic center of each helix predicted using
TM2ndS to a plane.
Optimization of rotational orientation of the TM regions. The rotational
orientation of the canonical helices was also optimized by using
Abbreviations: GPCR, G protein-coupled receptor; FF, force field; TM, transmembrane; DR,
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the multisequence hydrophobicity moments of the middle third
of each helix about their maximum hydrophobic center. This
analysis yielded a clear consensus on which residues should
contact the membrane and which residues should face the
receptor interior.
Optimization of helical bends and kinks. The kinks and bends in each
canonical helix was optimized with Newton–Euler inverse mass
operator (NEIMO) torsional dynamics (18, 19) or Cartesian
dynamics (described with the Dreiding FF and Charmm22
charges) for 500 ps at 300 K constant temperature, and we picked
the minimum energy conformation from the dynamics. The
helical bundle now has helices with bends and kinks. The
rotational orientation of these noncanonical helices was further
optimized by using both the procedure in step 4 followed by
energy-based optimization called ‘‘Rotmin’’ described in ref. 5.
In the energy-based rotational orientation optimization, we
performed systematic rotations on all of the seven helices over
5° at a time and over a small grid of rotation angles 50° to 50°.
At each rotation angle the side chains were added by using the
side chain placement program SCWRL5.0 (20) followed by poten-
tial energy minimization using conjugate gradients to 0.1 kcal
mol per Å rms deviation in force per atom. Steps 3, 4, and 6 are
part of a systematic search algorithm for optimum translational
and rotational orientation, and these steps allow conformational
search and aid in getting over large energy barriers between
various conformations of the TM barrel.
Equilibration of the optimized TM barrel. The optimized TM barrel
structure from the previous step was then equilibrated by
immersing it in a bilayer barrel of dilauroylphosphatidyl choline,
and the full system was optimized with rigid body quaternion
molecular dynamics, treating each molecule as a rigid body
for 50 ps at a constant temperature of 300 K using the MPSim
code (11).
Loop addition and final optimization. The interhelical loops were built
by using WHATIF (21), and disulfide bonds were formed between
Cys-107 in TM3 and Cys-182 in extracellular loop 2. This full
system was then optimized with the conjugate gradient minimi-
zation technique to 0.1 kcalmol per Å rms in force.
Prediction of Ligand Binding Sites and Binding Energies. Ligand
structure preparation. The 10 ligands shown in Fig. 1, were built
with CHEMDRAW, and the 2D structure was converted to 3D
structures by using POLYGRAF software. These ligands consist of
agonists dopamine, 7-hydroxydipropylaminotetralin, apomor-
phine, and bromocriptine and antagonists like clozapine, dom-
peridone, haloperidol, etc. We have categorized the antagonists
Fig. 1. Ten agonists and antagonists studied for the human dopamine D2 receptor.
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studied here into two classes: (i) class I, clozapine-like bulky
antagonists; and (ii) class II antagonists that have two aromatic
or ring moieties connected by a flexible linker with a protonated
amine group as in haloperidol. Hydrogens were added, and
Gasteiger charges were assigned to all of the ligands with
appropriate protonated states. We then minimized the potential
energy of each ligand using conjugate gradients to an rms
deviation in force of 0.1 kcalmol per Å.
Function prediction method for D2DR. HierDock protocol is a hier-
archical strategy ranging from coarse grain docking to fine grain
optimization for docking ligands in proteins and determining
their putative binding site. This method has been tested for
various GPCRs (3–5, 22), outer membrane protein A (23), and
globular proteins (24–28). (The protocol has been described in
detail in these references.) The version of HierDock used in this
study is described in ref. 4. In brief, the various steps of HierDock
version 2.0 protocol is as follows:
1. First we carried out a coarse grain docking procedure to
generate a set of conformations for ligand binding in the
receptor. Here we used DOCK4.0 (29) to generate and score
500 conformations, of which 50 (10%) were selected by using
a buried surface area cutoff of 90% and energy scoring from
DOCK4.0 for further analysis. The options used in DOCK4.0 are
flexible ligand docking with torsion drive and allowing four
bumps with the protein.
2. The 50 best conformations selected for each ligand from step
1 were subjected to all-atom minimization keeping the protein
fixed but the ligand movable. The solvation energy of each of
these 50 minimized conformations was calculated by using
analytical volume generalized born continuum solvation
method (14). Then the five best scoring conformations based
on the potential energy of the ligand in the protein were
selected from these 50 conformations for the next step.
3. Next we optimized the structure of the receptorligand
complex allowing the structure of the protein to accommo-
date the ligand. This was essential to identify the optimum
conformations for the complex. The all-atom receptorligand
energy minimization was performed on the 10 structures from
the previous step. Using these optimized structures, we
calculated the binding energy (BE) using the equation
BE PE (ligand in protein) PE (ligand in solvent) [1]
as the difference between the potential energy (PE) of the
ligand in the protein and the potential energy of the ligand in
water. The energy of the ligand in water is calculated by using
DREIDING FF and analytical volume generalized born
continuum solvation method.
4. Next we selected, from the five structures from step 3, the one
with the maximum number of hydrogen bonds between ligand
and protein. For this structure we used the SCREAM side chain
replacement program (V.W.T.K., N.V., and W.A.G., unpub-
lished observations) to reassign all side chains for the residues
within 5 Å in the binding pocket. (This uses a side-chain rotamer
library of 1,478 rotamers with 1.0-Å resolution, with the all-atom
DREIDING energy function to evaluate the energy for the
ligand–protein complex.) The binding energy of all of the five
optimized complexes was calculated by using Eq. 1.
Locating the putative binding site. To locate the binding site of
dopamine, other agonists, and antagonists, we scanned the entire
D2DR structure without any knowledge of the binding site. The
molecular surface of the entire receptor structure was mapped
by using autoMS utility of DOCK4.0. Spheres were generated to fill
up the void regions of the entire receptor using the sphgen utility
of DOCK4.0. The program PASS (30) was then used to locate
plausible centers of large void regions in the receptor. The
spheres that were within 5.0 Å of these centers were clustered for
docking of ligands. For D2DR we obtained nine regions where
we applied the only steps 1 and 2 of the HierDock protocol. The
best energy conformation for each ligand in each region was
selected based on (i) location of the binding site (those in the
intracellular loop or completely in the extracellular loop regions
were omitted for D2DR), (ii) buried surface area (90% cutoff
value was used), and (iii) interaction energy of the ligand with the
protein. If more than one region scanned had similar energies
within a certain tolerance factor, then both those regions were
chosen as putative binding regions. A tolerance of 30 kcalmol
was used because the minimization of the ligand with the fixed
receptor structure was done for only a fixed number of 50
conjugate gradient steps. Using this procedure we found similar
putative binding sites for agonists and class I antagonists
whereas, the predicted binding sites for class II antagonists were
different. Class II antagonists had three contiguous regions with
the best bound conformation having ligand–receptor interaction
energies within 30 kcalmol of each other. Hence, for these long
antagonists we merged the spheres of these three regions
together as the putative binding site. Because the number of
spheres in the merged region was high (300), the sphere density
was thinned to 100 spheres. Details of these energies will be
published elsewhere.
Prediction of binding sites and binding energies. Once the putative
binding sites were determined for agonists and antagonists, all of
the agonists and antagonists were docked into their respective
putative binding regions using HierDock protocol steps 1–4, and
the best five bound structures for each ligand was chosen. Herein
we performed iterative docking: the structure with side chains
replaced and minimized was used in the generation of a new
sphere set, and the target ligands were redocked to this opti-
mized binding structure by performing HierDock procedure
steps 1–4. This iterative HierDock procedure optimizes the side
chain conformation of the residues in the binding site for ligand
binding.
Results and Discussion
Fig. 2 shows the 3D structure of the human D2 DR predicted by
using MembStruk3.5 and the predicted binding site of dopamine
determined by using HierDock. During the scanning procedure
to determine the binding site, only one site was found to be
favorable for binding dopamine and other agonists studied.
Thus, the predicted binding site of dopamine is located in the top
third of the 7-TM barrel involving TM domains 3–6. The amino
acid residues within 5.5 Å of the dopamine binding site in D2DR
are shown in Fig. 3. We found the following residues to be
essential for binding of dopamine in the human D2 receptor.
1. Asp-114 in TM3. The carboxyl group of the aspartate forms
a tight salt bridge (2.6 Å) with the primary amino group of
dopamine. This residue is conserved over all five human DRs,
as well as in all human biogenic amine receptors. Mutation
studies have implicated this residue in the direct binding of the
dopamine to D2DR (31).
2. Ser-193 and Ser-197 in TM5. These residues hydrogen-bond
to the metahydroxyl (2.7 Å) and parahydroxyl (2.7 Å) groups,
respectively, of the catechol ring of dopamine, playing an
essential role in recognizing dopamine. These two residues
are conserved over all five human DRs and have been shown
to be involved in direct binding of ligand through mutation
studies (31). Ser-194 is also conserved over all five human
DRs, and mutation studies indicate that it is involved in
binding of the ligand. In our structure, Ser-194 is hydrogen-
bonded to the backbone nitrogen of residue 192 rather than
dopamine. However, Ser-194 might serve as an alternate to
Ser-193 in hydrogen bonding to the metahydroxyl group of
the catechol for the slightly modified structure of the receptor
that might result from activation.







3. Phe-110, Met-117, Cys-118 (TM3), Phe-164 (TM4), Phe-189,
Val-190 (TM5), Trp-386, Phe-390, and His-394 (TM6) form
a mostly hydrophobic pocket for dopamine. We find Trp-386
and Phe-390 of the conserved WXXFF motif on TM6 to be
within the 4.5-Å binding pocket, but Phe-389 is 7.2 Å away
from dopamine.
Thus, the predicted binding site (involving TM domains 3–6)
is in excellent agreement with the residues determined experi-
mentally to be involved in binding (31–38). This provides a good
validation of the predicted structure for D2DR and of the
predicted binding site of dopamine. We also carried out full
HierDock predictions for the binding sites or three other known
agonists: apomorphine, 7-hydroxydipropylaminotetralin, and
bromocriptine, and we found very similar active sites. In partic-
ular, all dopamine agonists bind tightly to both Ser-193 and
Ser-197 in TM5 in addition to Asp-114 in TM3 just as in
dopamine. These predicted structures can be further tested by
selective mutation of some of the additional residues we have
identified in the active site.
To further validate the predicted structure for D2DR, we used
the HierDock procedure to predict the binding conformation
and the binding energy for seven well-studied antagonists. We
found two classes of antagonists.
Class I antagonists (exemplified by clozapine) occupy the
region between TM3, TM4, TM5, and TM6 (the agonist binding
pocket). Thus, clozapine makes (i) a 2.8-Å salt bridge to Asp-114
(TM3); (ii) a hydrogen bond to Ser-193 (TM5) (3.2 Å) but not
to Ser-194 or Ser-197; (iii) heteroatom interactions with Trp-386
(TM6) (3.1 Å); and (iv) a mostly hydrophobic pocket shown in
Fig. 4 formed by Val-87 and Trp-90 (TM2), Phe-110, Leu-113,
Val-115, Met-117, and Cys-118 (TM3), Phe-164 (TM4), Phe-189,
Val-190, Ser-194, and Ser-197 (TM5), Phe-382, Trp-386, Phe-
389, and Phe-390 (TM6), and Thr-412, Trp-413, Tyr-416, and
Ser-419 (TM7).
Fig. 2. Predicted binding site of dopamine (shown in spheres) in the predicted structure of human dopamine D2 receptor.
Fig. 3. Residues within 5.5 Å of the dopamine binding site in the human
dopamine D2 receptor. The numbers shown in parentheses are the TM helix
to which the residue belongs. The distance between Asp-114 and the primary
amine group in dopamine is 2.6 Å. Ser-193 on TM5 makes a 2.7-Å hydrogen
bond with the metahydroxyl group, and Ser-197 makes a 2.7-Å hydrogen
bond to the parahydroxyl group of dopamine. Fig. 4. Residues within 5.5 Å of clozapine bound to human D2DR.
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Class II antagonists, exemplified by haloperidol, occupy the
region between TM2, TM3, TM6, and TM7, with minimal contacts
to TM4 and TM5. Thus, haloperidol makes (i) a 2.8-Å salt bridge
to Asp-114 (TM3); (ii) a hydrogen bond (3.2 Å) to Ser-197 (TM5)
(3.2 Å) but not to Ser-193 or Ser-194; (iii) heteroatom interactions
with Trp-386 (TM6) at 3.8 Å and Trp-90 (TM2) at 3.0 Å; and (iv)
a mostly hydrophobic pocket (as shown in Fig. 5) provided by
Val-87, Val-91, and Leu-94 (TM2), Phe-110, Leu-113, Val-115,
Met-117, and Cys-118 (TM3), Trp-160 and Phe-164 (TM4), Phe-
189, Val-190, and Val-196 (TM5), Trp-386, Phe-389, Phe-390, and
His-393 (TM6), and Ser-409, Thr-412, Trp-413, Tyr-416, and Val-
417 (TM7). Other class II antagonists with very similar binding sites
include spiperone and sulpiride. Interestingly, many class II antag-
onists have been shown to crossreact with other aminergic receptors
and other class A GPCRs. In some GPCRs, CCR1 for example, the
conserved TM3 Asp is replaced with a longer-chain Glu. From
distant restraints and structural considerations it appears that a
longer linker alkyl chain in the ligand would push the protonated
amino group of the ligand closer to the TM2 and TM7, and this
would alleviate binding to those GPCRs with a conserved Asp in
this position on TM3. However, this longer alkyl chain ligand would
bind better and be specific to GPCRs with Glu in this position.
The residues we found to be important for binding of agonists
and antagonists are consistent with all available data from
substituted cysteine accessibility method, radiolabeling, and
mutation experiments (31) on these receptors. All seven antag-
onists make a tight contact to Asp-114 in TM3, but none forms
strong contacts to both Ser residues in TM5, in contrast with our
observation that all agonists have strong coupling to Asp in TM3
and both Ser in TM5. This finding suggests that strong coupling
between TM3 and TM5 is essential for dopaminergic transduc-
tion (consistent with experiments showing that hydrogen bonds
to both conserved serines of TM5 are essential for dopamine
activation) (31–38). The predicted structures for antagonists
lead to a weakening of the coupling between TM3 and TM5 and
(particularly for class II antagonists) prevent motion between
TM3 and TM6.
Based on the criteria that a salt bridge to TM3 and two
hydrogen bond contacts to TM5 are both essential for activation,
whereas the salt bridge and one hydrogen bond are important for
antagonists, we can categorize all ligands as agonists and antag-
onists. This criteria correctly predict the nature of all ligands
studied here. Recently, an agonist in the dipropylaminotetralin
series (39) has been reported with no hydroxyl group. This
finding may indicate a more complicated criterion for agonists
and will be studied later.
Fig. 6 shows the calculated binding energies (relative to
dopamine), for the nine ligands with experimental dissociation
constants. It is clear from Fig. 6 that the experimental dissoci-
ation constant varies over several orders of magnitude for a given
ligand. However, we found that the calculated binding energies
always fall within the range of experimental binding constants.
Taking dopamine into account, the best correlation factor
calculated is 0.92, with bromocriptine as an outlier to this fit. This
good correlation provides additional validation for the predicted
structure and function.
In summary, the predicted first-principles structure of D2DR
leads to correct predictions of the critical residues for binding
dopamine and several antagonists (as identified by mutation
studies) and gives relative binding affinities that correlate fairly
well with experiments. It should be noted that, given the
approximations in the calculated binding energies, one can
distinguish a very good binder from a very weak binder but
cannot distinguish ligands with similar binding affinities. We
found that the predicted binding site of dopamine and other
agonists is located between TM helices 3, 4, 5, and 6 but that the
strongest binding antagonists bind to a site involving TM helices
2, 3, 4, 6, and 7, with minimal contacts to TM5. We identify the
characteristic differences between the binding sites of agonists
and antagonists, because agonists involve tight binding between
helices 3 and 5 whereas antagonists involve tight binding of
ligand between TM helices 3 and 6.
The validation of the predictions for D2 justify carrying out
similar studies to predict the structures and ligand binding to the
other four human DRs. We hope that this study will provide a
basis for designing agonists and antagonists selective to binding
to just one of the five DR subtypes, which could be of tremen-
dous value in treating dopamine-related diseases while minimiz-
ing side effects.
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